N-adamant-1-y1-N1-[4-chlorobenzothiazol-2-y1] urea useful in the treatment of inflammation and as an anticancer radiosensitizing agent
US6214851A · kind A · utility
5Cited by
2References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 17, 2000 |
| Grant date | Apr 10, 2001 |
| Priority date | — |
| Expiry date | Mar 17, 2020 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates generally to N-adamant-1-yl-N'-[4-chlorobenzothiazol-2-yl] urea, pharmaceutical compositions comprising the same, and methods of using the same in the treatment of inflammation and as an anticancer radiosensitizing agent.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.